GLP1R and type 2 diabetes mellitus: Once-weekly administration of tirzepatide (LY3298176), a dual GIP/GLP-1 co-agonist, for 26 weeks significantly reduced HbA1c and body weight in a dose-dependent way, and at the highest dose (15 mg) reduced total cholesterol and TG concentrations in comparison both with placebo and dulaglutide 1.5 mg in patients with T2D [84].